IcICLLe looks at the mechanism of action of ibrutinib. Ibrutinib has been tested previously in clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL) patients, but the way it works is still unknown. This initial phase is fully recruited.
The aim of the IcICLLe Extension Study is to investigate the effectiveness and safety of ibrutinib used in combination with obinutuzumab in patients with CLL who are relapsed/refractory. The trial may also give us information about how using both of the drugs together affects the rate of growth, and the lifespan, of leukaemia cells.
New patients can only register to the Extension Study.
Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible
| Chief Investigator: |
Professor Peter Hillmen |
| Sponsor: |
University of Birmingham |
| Funders: |
TAP Bloodwise |
| Disease Site: |
Chronic Lymphocytic Leukaemia |
| Trial Type: |
Clinical Trial of an Investigational Medicinial Product |
| Status: |
Open |
| UKCRN Study ID: (if applicable) |
15429 |
| Open to new sites? |
No |
| Recruitment start date: |
12 June 2014 |
| Anticipated Recruitment end date |
31 January 2017 |
| CRCTU Trial Management Team: |
Haematology |
| Trial E-mail Address: |
IcICLLe@trials.bham.ac.uk |